X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13957) 13957
Publication (1785) 1785
Book Review (95) 95
Book Chapter (88) 88
Conference Proceeding (41) 41
Book / eBook (11) 11
Dissertation (8) 8
Magazine Article (5) 5
Trade Publication Article (4) 4
Web Resource (4) 4
Data Set (2) 2
Newspaper Article (2) 2
Paper (2) 2
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8341) 8341
index medicus (6916) 6916
animals (5925) 5925
poly polymerase (5681) 5681
poly polymerases - metabolism (5280) 5280
apoptosis (5147) 5147
oncology (3309) 3309
apoptosis - drug effects (2985) 2985
mice (2971) 2971
biochemistry & molecular biology (2945) 2945
cancer (2780) 2780
poly polymerase inhibitors (2561) 2561
cell line, tumor (2525) 2525
cell biology (2505) 2505
female (2369) 2369
male (2093) 2093
proteins (2005) 2005
dna damage (1943) 1943
activation (1891) 1891
poly polymerase-1 (1841) 1841
dna repair (1783) 1783
rats (1516) 1516
oxidative stress (1457) 1457
enzyme inhibitors - pharmacology (1420) 1420
expression (1411) 1411
caspases - metabolism (1407) 1407
inhibition (1315) 1315
pharmacology & pharmacy (1314) 1314
antineoplastic agents - pharmacology (1249) 1249
article (1246) 1246
cell death (1223) 1223
cell line (1190) 1190
research (1180) 1180
cell survival - drug effects (1164) 1164
caspase (1140) 1140
deoxyribonucleic acid--dna (1125) 1125
dna (1120) 1120
poly polymerases - genetics (1117) 1117
tumors (1097) 1097
gene expression (1093) 1093
chemotherapy (1087) 1087
ribose (1080) 1080
signal transduction (1072) 1072
phosphorylation (1068) 1068
analysis (1061) 1061
cells, cultured (1052) 1052
cells (1048) 1048
breast cancer (1031) 1031
death (1013) 1013
cell cycle (1010) 1010
caspase 3 - metabolism (988) 988
mutation (985) 985
blotting, western (974) 974
cell proliferation - drug effects (958) 958
dose-response relationship, drug (946) 946
multidisciplinary sciences (920) 920
polymerase (915) 915
research article (909) 909
dna-damage (908) 908
caspase-3 (902) 902
kinases (886) 886
inhibitors (873) 873
caspase 3 (845) 845
parp (842) 842
mitochondria (838) 838
poly (815) 815
in-vitro (814) 814
health aspects (811) 811
medicine (807) 807
monosaccharides (799) 799
repair (797) 797
genetic aspects (794) 794
homologous recombination (791) 791
sugars (791) 791
cell-death (786) 786
enzymes (764) 764
enzyme activation (753) 753
cytotoxicity (744) 744
neurosciences (743) 743
tumor cells, cultured (743) 743
care and treatment (724) 724
benzamides - pharmacology (715) 715
apoptosis - physiology (710) 710
signal transduction - drug effects (709) 709
biology (707) 707
poly polymerase 1 (707) 707
flow cytometry (698) 698
adp (697) 697
time factors (668) 668
reactive oxygen species - metabolism (663) 663
science (648) 648
toxicology (640) 640
protein (625) 625
cancer therapies (624) 624
cell proliferation (623) 623
nf-kappa-b (623) 623
proto-oncogene proteins c-bcl-2 - metabolism (623) 623
physiological aspects (616) 616
mitochondria - metabolism (611) 611
enzyme activation - drug effects (598) 598
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13862) 13862
Chinese (48) 48
French (36) 36
Japanese (19) 19
Russian (17) 17
German (13) 13
Korean (7) 7
Polish (7) 7
Hungarian (4) 4
Ukrainian (3) 3
Czech (2) 2
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Gynecological Cancer, ISSN 1048-891X, 06/2019, Volume 29, Issue 5, pp. 956 - 968
The use of poly(ADP-ribose) polymerase (PARP) inhibition is transforming care for the treatment of ovarian cancer, with three different PARP inhibitors (PARPi)... 
medical oncology | ovarian cancer | POLY(ADP-RIBOSE) POLYMERASE | DOSE-ESCALATION | ONCOLOGY | DOUBLE-BLIND | PHASE-II | PLATINUM-SENSITIVE OVARIAN | RECURRENT EPITHELIAL OVARIAN | MAINTENANCE THERAPY | PRIMARY PERITONEAL | NEGATIVE BREAST-CANCER | PARP INHIBITOR | OBSTETRICS & GYNECOLOGY
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 14, pp. 2972 - 2978
Abstract Background Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the... 
Hematology, Oncology and Palliative Medicine | PARP-inhibitor | Breast | Olaparib | Ovarian | Phase 1 | Anti-angiogenic | Cediranib | CELLS | SOLID TUMORS | BEVACIZUMAB | DOWN-REGULATION | BRCA1 | HYPOXIA | RAD51 | ONCOLOGY | HOMOLOGOUS RECOMBINATION | DNA-REPAIR | Piperazines - administration & dosage | Receptors, Estrogen - metabolism | Nausea - chemically induced | Tablets | Humans | Middle Aged | Ovarian Neoplasms - pathology | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - chemically induced | Diarrhea - chemically induced | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Capsules | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Quinazolines - administration & dosage | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Treatment Outcome | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoplasms, Glandular and Epithelial - drug therapy | Quinazolines - adverse effects | Carcinoma, Ovarian Epithelial | Aged | Phthalazines - adverse effects | Antimitotic agents | Product development | Breast cancer | Antineoplastic agents | Vascular endothelial growth factor | Sugars | Monosaccharides | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2016, Volume 22, Issue 15, pp. 3894 - 3902
Journal Article
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ISSN 0006-291X, 05/2019, Volume 513, Issue 2, pp. 340 - 346
Dysfunction of histone methylation is known to be related to cancer progression. The histone methyltransferase SMYD2 methylates histone protein H3 and... 
Poly ADP ribose polymerase inhibitor | High-grade serous ovarian carcinoma | BIOCHEMISTRY & MOLECULAR BIOLOGY | Non-histone methylation | CELL-PROLIFERATION | LLY-507 | CANCER | BIOPHYSICS | PATHWAY | LYSINE METHYLATION | Histone methyltransferase | SMYD2 | EXPRESSION | Apoptosis | EZH2
Journal Article
Journal Article
Biochemistry (Moscow), ISSN 0006-2979, 2/2018, Volume 83, Issue 2, pp. 152 - 158
Journal Article
Current Opinion in Obstetrics and Gynecology, ISSN 1040-872X, 02/2018, Volume 30, Issue 1, pp. 7 - 16
Journal Article
Molecular Neurobiology, ISSN 0893-7648, 12/2018, Volume 55, Issue 12, pp. 9156 - 9168
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after ischemic stroke remain limited due to a narrow therapeutic window, low... 
Neurology | Neurosciences | Stroke | Recombinant tissue plasminogen activator | Biomedicine | Reperfusion | Neurobiology | Vasculoprotection | Cell Biology | TISSUE-PLASMINOGEN ACTIVATOR | FOCAL CEREBRAL-ISCHEMIA | BLOOD-BRAIN-BARRIER | NEUROSCIENCES | HEMORRHAGIC TRANSFORMATION | POLYMERASE-1 PARP-1 | ACUTE ISCHEMIC-STROKE | VASCULAR FUNCTION | SUBARACHNOID HEMORRHAGE | CELL-ADHESION MOLECULES | PARP INHIBITORS | Edema - complications | Neuroprotective Agents - therapeutic use | Recombinant Proteins - therapeutic use | Inflammation - pathology | Thrombosis - complications | Stroke - complications | Male | Tissue Plasminogen Activator - therapeutic use | Vasospasm, Intracranial - complications | Stroke - pathology | Proteolysis - drug effects | Neuroprotective Agents - pharmacology | Infarction, Middle Cerebral Artery - drug therapy | Phenanthrenes - therapeutic use | Endothelial Cells - metabolism | Hemorrhage - complications | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Edema - drug therapy | Stroke - drug therapy | Infarction, Middle Cerebral Artery - pathology | Recombinant Proteins - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Recombinant Proteins - administration & dosage | Phenanthrenes - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Thrombosis - pathology | Hemorrhage - drug therapy | Animals | Tissue Plasminogen Activator - pharmacology | Mice | Thrombosis - drug therapy | Edema - pathology | Hemorrhage - pathology | Vasospasm, Intracranial - drug therapy | Vasospasm, Intracranial - pathology | Endothelial Cells - drug effects | Immunohistochemistry | Edema | Vascular cell adhesion molecule 1 | Cortex | Vasoconstriction | Poly(ADP-ribose) polymerase | Thrombin | Injection | ADP | Hemorrhage | Thrombolysis | t-Plasminogen activator | Cell adhesion molecules | Cell adhesion & migration | Ischemia | Blood-brain barrier | Ribose | Sensorimotor system | Combined treatment | Brain injury
Journal Article
Journal Article